MN-AYMIUM
9.5.2022 12:02:04 CEST | Business Wire | Press release
Aymium , the leading producer of renewable biocarbon products, announced that it has entered a long-term supply contract for its patented, coal replacement product with Hokuriku Electric Power Company and Nippon Steel Trading . The contract is the largest for advanced biocarbon globally and will support the first large-scale continuous utility use of advanced biocarbon to replace coal in power generation. Aymium produces the only demonstrated carbon-negative product for replacing coal in power generation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509005317/en/
“Hokuriku’s pioneering use of Aymium’s leading-edge products to replace coal will accelerate transition away from fossil-fuel-based power generation and reduce environmental impacts,” said Aymium CEO James Mennell . “Aymium’s products allow immediate replacement of coal with a renewable, carbon-negative product. Our collaboration with Hokuriku and Nippon Steel Trading advances our shared mission of decarbonization and global environmental improvement.”
Each ton of Aymium’s product, when used in place of coal, results in a reduction of over 2.5 tons of CO2 as well as over 95% reduction in emission of other pollutants from coal-generated power, including sulfur dioxide and mercury.
The landmark contract and associated environmental benefits were celebrated by U.S. Ambassador to Japan Rahm Emanuel . “Hokuriku Electric Power’s agreement to purchase Aymium’s innovative renewable biocarbon products is a win for U.S. jobs, the environment, and U.S. exports. Japanese investment in Aymium’s innovative technology, from both Hokuriku Electric Power and Nippon Steel Trading, shows the power of U.S. – Japan cooperation,” said Ambassador Emanuel.
Aymium’s renewable product is created through a non-combustion process that converts biomass to high purity biocarbon and biogas, recovers and recycles water from the biomass, and is powered by self-generated renewable energy. The product has been tested at power-plant scale by Hokuriku, confirming suitability and advantages as a replacement for fossil coal.
“Hokuriku is committed to decarbonization, and strengthening our relationship with Aymium, whose patented technology shows high growth potential and contributes to Hokuriku’s efforts to become carbon neutral,” said Mr. Koji Matsuda, Executive President and Representative Director, Hokuriku Electric Power Company.
Hokuriku also announced an equity investment in Aymium. Hokuriku’s investment follows $200 million from investors by major global energy and metals companies with a focus on decarbonization, including Nippon Steel , Rio Tinto and Steel Dynamics .
“As partners to this contract, and investors in Aymium, Nippon Steel Trading is showing its commitment to advance carbon-reduction technologies that will have an immediate and near-term benefit,” said Mr. Yasumitsu Saeki, President and Representative Director, Nippon Steel Trading Corporation. Nippon Steel Trading is acting as Aymium’s and Hokuriku’s trading partner and managing international logistics for the supply to Hokuriku.
Aymium is a Minnesota-based cleantech company that creates renewable products that replace fossil fuels and reduce the environmental impact of large global industries including metals, energy, and crop production. Aymium’s products are protected by more than 275 issued and pending patents globally and are engineered to immediately displace fossil coal in energy production — without the need for any type of plant modifications. Aymium’s patented process converts certified sustainably sourced renewable biomass into biocarbon using integrated thermolysis.
Aymium is constructing two additional production facilities — one in Williams, California, and another in the Pacific Northwest — to produce advanced biocarbon for use by Hokuriku. Aymium anticipates investing over $350 million to construct the facilities that are scheduled to be operational in 2023.
Aymium produces high-value biocarbon and biohydrogen products that can be used to immediately replace fossil fuels in the production of metals, energy, crops, and in the purification of water and air with no modifications to equipment or processes. Produced using sustainably sourced biomass — recovered and unusable wood — Aymium’s bioproducts are renewable, carbon-negative, and they replace emission-heavy fossil fuels such as coal and coke. Aymium’s leading technology is backed by more than 275 issued or pending patents on a global basis. Aymium is headquartered in Minnesota.
About Hokuriku Electric Power Company
Established in 1951, Hokuriku Electric Power Company is a comprehensive energy company that aims to contribute to the development of the Hokuriku region through the stable supply of affordable and high-quality energy. The company's vision for the future is to “develop together with Hokuriku and deliver new value nationwide and overseas,” and it is expanding its business beyond the existing electric power business while contributing to social issues such as addressing the global warming, sustainable development of the region, and the realization of a smart society.
About Nippon Steel Trading Corporation
Nippon Steel Trading Corporation is the core trading company of NIPPON STEEL CORPORATION Group, and was established in October 2013 through the merger of Nippon Steel Trading Co., Ltd. and Sumikin Bussan Corporation. The company continues to grow as a multiple specialty trading company operating four integrated core businesses: steel, industrial supply & infrastructure, textiles, and foodstuffs.
Forward-Looking Statements
This press release contains some predictive statements about future events, including statements related to new facilities and environmental impact. These statements, which are generally preceded or accompanied by such typical conditional words as "anticipate", "intend", "believe", "estimate", "plan", "seek", "project", or "expect", or by the words "may", "will", or "should", are intended to be made as "forward-looking," subject to many risks and uncertainties, within the safe harbor protections of the Private Securities Litigation Reform Act of 1995. These statements speak only as of this date and are based upon currently available information and assumptions, which we consider reasonable as of this date. Such predictive statements are not a guarantee of future performance, and we undertake no duty to update or revise any such statements. There are many factors that could cause such forward-looking statements to turn out differently than anticipated.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005317/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
